Highest-materiality recent filing
Zivo Bioscience to voluntarily deregister, cease SEC reporting; CFO and director resign
CFO William Sullivan resigns effective March 30, 2026; board member Alison Cornell resigns immediately as part of cost-cutting measures.
CFO Keith Marchiando resigns; William Sullivan appointed Interim CFO
Keith Marchiando resigns as CFO effective Dec 31, 2025; receives $27,040/mo through Dec 31, 2026.
ZIVO CEO letter highlights algae antioxidant validation and animal health progress
Independent analysis showed ZIVO's algae has nearly double SOD activity vs. a competing algae product.
Director Nola Masterson resigns from Zivo Bioscience board effective August 12, 2025
Ms. Masterson resigned immediately; no disagreement with company operations, policies, or practices.
Zivo Bioscience raises $250k initial tranche in $2M convertible debt offering
Issued $250k bridge promissory note with 10% annual interest, compounded annually; due after 2 years or upon $5M+ equity financing.
Elected John B. Payne and Alison A. Cornell as Class III directors with 1,681,190 and 1,681,001 votes for, respectively; broker non-votes 792,911.
Zivo Bioscience issues 191,698 shares, raises ~$1.5M from accredited investor since Nov 2024
Sold 75,000 shares at $20.19 each to one accredited investor, gross proceeds ~$1.5M.
Zivo Bioscience swaps revenue share obligations for 212,260 shares; director affiliates participate
Company authorized exchange of up to 212,260 shares for cancellation of Participation Agreements with accredited investors.
ZIVO BIOSCIENCE moves principal executive office to Troy, Michigan
Effective January 6, 2025, principal executive office changed to 2125 Butterfield Drive, Suite 100, Troy, MI 48084.
Zivo restructures $277k debt into unsecured notes payable over 24 months at 1%
Debt Settlement Agreements with three creditors executed on Nov 12, 2024.
Zivo Bioscience sells 169,022 unregistered shares at avg $10.44 to accredited investors
Sold 169,022 shares between Aug 22 and Oct 17, 2024, at $8.34 to $16.31 per share (avg $10.44).
ZIVO Bioscience appoints Laith Yaldoo to board, expands to 5 members
Board increased from 4 to 5 members; Laith Yaldoo appointed effective July 11, 2024.
Zivo shareholders elect Masterson as director, ratify BDO, approve say-on-pay
Nola E. Masterson elected Class II director (1,155,796 for, 80,935 withheld; 625,589 broker non-votes).
Zivo Bioscience amends 8-K to correct date typo in director stock award from 2023
Corrects date in Item 1.01 from erroneous date to December 29, 2023.
Adopted 2024 Director Equity Plan (875k shares, auto-increase 5%/yr). Director cash fee raised from $40k to $50k, eligible for restricted stock/RSUs.
Nasdaq formally delists Zivo Bioscience common stock and warrants
Nasdaq announced formal delisting on Feb 13, 2024; will file Form 25 with SEC.
Zivo Bioscience sells 174,145 unregistered shares to accredited investors at avg $3.05/share
Sold 174,145 common shares at $2.82–$4.02 each (avg $3.05), relying on Section 4(2) and Regulation D.
Zivo Bioscience sells 288,359 unregistered shares at avg $1.27 to accredited investors
Sold 288,359 shares of common stock between Dec 29, 2023 and Jan 3, 2024.
Zivo raises ~$309k via private placement of 266,324 shares at avg $1.16
Sold 266,324 shares at prices between $1.00 and $1.35 per share (avg $1.16) to accredited investors.
Zivo closes $200,000 private placement of 200,000 shares at $1.00 each
Sold 200,000 common shares at $1.00 per share to an accredited investor on Dec 5, 2023.
ZIVO Bioscience receives Nasdaq delisting notice; shares to trade on OTC Pink Sheets
Nasdaq notified ZIVO on Nov 22, 2023 of delisting for noncompliance with Listing Rule 5550(b)(1).
Zivo Bioscience issues $150,000 10% promissory note to HEP Investments
Principal amount $150,000; interest at 10% per annum; matures May 16, 2024.
Zivo Bioscience effects 1-for-6 reverse stock split to regain Nasdaq compliance
1-for-6 reverse split effective 5:00 p.m. ET Oct 26, 2023; trading split-adjusted Oct 27.
Zivo Bioscience granted Nasdaq extension to Nov 20, 2023 to regain equity compliance
Received deficiency notice on May 23, 2023 for stockholders' equity below $2.5M (Listing Rule 5550(b)).
ZIVO Bioscience raises ~$4.0M in registered direct offering and concurrent private placement
Sold 1,498,130 shares/pre-funded warrants at $2.67/unit to institutional investor for ~$4.0M gross proceeds.
Zivo Bioscience stockholders elect Maggiore, ratify BDO, approve exec compensation
Christopher D. Maggiore elected to board with 3,050,053 votes for, 393,297 withheld; 2,704,419 broker non-votes.
Zivo Bioscience receives Nasdaq delisting notice for $2.5M equity non-compliance
Nasdaq notified Zivo on May 23, 2023 that it fails to meet $2.5M stockholders' equity requirement (Listing Rule 5550(b)).
Zivo Bioscience receives $1M bridge loan from CEO John Payne with 10% interest and warrants
CEO John Payne provides $1M unsecured six-month loan at 10% simple interest, extendable six months.
ZIVO BIOSCIENCE announces study results; full details not in filing excerpt
Press release dated February 10, 2023 issued regarding results of a recent study.
Zivo Bioscience receives Nasdaq delisting notice for insufficient equity
Nasdaq notified Zivo on Nov 22, 2022 of non-compliance with minimum $2.5M stockholders' equity requirement.
Zivo Bioscience receives USDA CVB jurisdiction for coccidiosis biologic; new study in Sept 2022
USDA CVB affirms jurisdiction over novel immune-modulating biologic for coccidiosis in broilers, removing regulatory ambiguity.
Zivo Bioscience shareholders elect four directors, ratify BDO as auditor
Elected Maggiore (Class I), Masterson (Class II), Payne and Cornell (Class III) to board with 3.4M+ votes for each.
Zivo Bioscience adopts staggered board, eliminates shareholder written consent
Board approved Second Amended and Restated Bylaws effective June 30, 2022.
Zivo Bioscience sets 2022 Annual Meeting for July 28; new deadlines for proposals and nominations
Annual Meeting scheduled for July 28, 2022; record date fixed as June 28, 2022.
Submitted white paper to USDA for poultry coccidiosis product; expects jurisdiction confirmation within 8 weeks.
ZIVO regains Nasdaq compliance after late 10-K filing cured
Received noncompliance notice on April 19, 2022 for failing to timely file 2021 10-K.
Zivo Bioscience restates Q3 2021 financials; delays 2021 10-K filing
Error in accounting for License Co-Development Participation Agreements; restates net loss for Q3 2021 from -$1.93M to -$1.58M.
Zivo reaffirms former CEO Andrew Dahl was terminated for cause, disputes his email claims
Company states Board terminated Andrew Dahl for cause; he was offered chance to resign before termination.
Zivo Bioscience terminates CEO Andrew Dahl for cause; Dahl resigns from board
CEO Andrew A. Dahl terminated for cause on Jan 4, 2022 after declining to resign; no separation agreement reached.
Zivo Bioscience appoints BDO as auditor and finalizes CEO John Payne's employment contract
Appointed BDO USA, LLP as independent auditor effective February 10, 2022, replacing resigned auditor Wolinetz, Lafazan & Company.
ZIVO Bioscience terminates CEO Andrew Dahl; Chairman John Payne named President and CEO
Andrew A. Dahl terminated as President and CEO on January 4, 2022.
Zivo Bioscience auditor Wolinetz, Lafazan resigns on Nov 30, 2021
Wolinetz, Lafazan & Company resigned as independent auditor effective Nov 30, 2021, citing personal reasons.
Zivo Bioscience's auditor Wolinetz, Lafazan resigns effective Nov 30, 2021; no disagreements
Independent auditor Wolinetz, Lafazan & Company resigned on Nov 30, 2021 for personal reasons unrelated to Zivo.
Zivo Bioscience reports shareholder votes: directors elected, equity plan approved, auditor ratified
All five director nominees elected with >95% votes for (excluding broker non-votes).
Zivo Bioscience files 8-K on annual meeting presentation; no specifics disclosed
Presentation delivered at October 12, 2021 Annual Meeting of Shareholders.
Zivo Bioscience director Rondeau resigns; board reduced to 5; committee appointments
Rondeau resigned effective Sep 17, 2021; no disagreement with company operations.
Zivo Bioscience board adopts annual say-on-pay vote frequency
Shareholders cast most votes for annual say-on-pay frequency at Nov 2020 meeting.
On July 11, 2024, the Board of Directors of ZIVO Bioscience Inc., (the “Company”) increased its size from four (4) to five (5) members and appointed Laith Yaldoo to fill the vacancy.
The Company reaffirms that the Board terminated Dahl for cause.
on February 18, 2022, Mr. Dahl resigned from his position as a member of the Company’s board of directors.
the Company terminated the employment of Andrew A. Dahl, the President and Chief Executive Officer of the Company.
Effective as of January 7, 2022, the Board of the Company appointed Mr. John B. Payne as the Company’s President and Chief Executive Officer.
On January 4, 2022, Zivo Bioscience, Inc. (the “Company” ) terminated the employment of Andrew A. Dahl, the President and Chief Executive Officer of the Company.
On September 16, 2021, Mr. Rondeau gave notice of his intent to resign from the Board of Directors (the “Board”) of Zivo Bioscience, Inc. (the “Company”) effective on September 17, 2021.
Max materiality 0.85 · Median 0.50 · Most common event other_material